Of these, SMO mutations are associated with the anterior skull base, have been shown to have an impact on the onset of tumor recurrence [3, 42] and both AKT1E17K and SMO are currently investigated as candidates for targeted therapy (ClinicalTrials.gov: NCT02523014). Here, SMO is linked to neoplasm.